A novel method for identifying SARS-CoV-2 infection mutants via an epitope-specific CD8+ T cell test

IF 3.5 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Congling Qiu , Bo Peng , Chanchan Xiao , Pengfei Chen , Lipeng Mao , Xiaolu Shi , Zhen Zhang , Ziquan Lv , Qiuying Lv , Xiaomin Zhang , Jiaxin Li , Yanhao Huang , Qinghua Hu , Guobing Chen , Xuan Zou , Xiaofeng Liang
{"title":"A novel method for identifying SARS-CoV-2 infection mutants via an epitope-specific CD8+ T cell test","authors":"Congling Qiu ,&nbsp;Bo Peng ,&nbsp;Chanchan Xiao ,&nbsp;Pengfei Chen ,&nbsp;Lipeng Mao ,&nbsp;Xiaolu Shi ,&nbsp;Zhen Zhang ,&nbsp;Ziquan Lv ,&nbsp;Qiuying Lv ,&nbsp;Xiaomin Zhang ,&nbsp;Jiaxin Li ,&nbsp;Yanhao Huang ,&nbsp;Qinghua Hu ,&nbsp;Guobing Chen ,&nbsp;Xuan Zou ,&nbsp;Xiaofeng Liang","doi":"10.1016/j.bsheal.2024.03.005","DOIUrl":null,"url":null,"abstract":"<div><p>Since the outbreak of the coronavirus disease 2019 (COVID-19) epidemic in 2019, the public health system has faced enormous challenges. Tracking the individuals who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key step for interrupting chains of transmission of SARS-CoV-2 and reducing COVID-19-associated mortality. With the increasing of asymptomatic infections, it is difficult to track asymptomatic infections through epidemiological surveys and virus whole-genome sequencing. However, due to the cross-reactivity of neutralizing antibodies produced by multiple virus subtypes, neutralizing antibody detection cannot be used to determine whether an individual has a history of infection with a specific subtype of SARS-CoV-2. We recruited 4 human leukocyte antigen A2 (HLA-A2) infections, 15 individuals who received three doses of inactivated vaccines, and 30 breakthrough infections after vaccination and discussed a case-tracking approach to detect epitope-specific CD8<sup>+</sup> T cells in the peripheral blood of close contacts, including accurate HLA typing based on ribonucleic acid (RNA)-sequencing and flow cytometry data and the comparison and characterization of SARS-CoV-2 HLA-A2 and HLA-A24 epitope-specific CD8<sup>+</sup> T cells. From individuals who received three doses of inactivated vaccine, we observed that the CD8<sup>+</sup> T cell specificity for ancestral epitopes was significantly higher than for mutated epitopes, and the fold change of CD8<sup>+</sup> T cells corresponding to mutated epitopes relative to ancestral epitopes was less than 1. The enzyme-linked immunospot (ELISpot) results further validate this result. This study forms a “method for understanding the infection history of SARS-CoV-2 subtypes based on the proportion of epitope-specific CD8<sup>+</sup> T cells in the peripheral blood of subjects”, covering up to 46 % of the population, including HLA-A2<sup>+</sup> and HLA-A24<sup>+</sup> donors, providing a novel method for SARS-CoV-2 infected case tracing.</p></div>","PeriodicalId":36178,"journal":{"name":"Biosafety and Health","volume":"6 3","pages":"Pages 143-152"},"PeriodicalIF":3.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590053624000326/pdfft?md5=f1efcb418ab5e241a7316a79df11a3a4&pid=1-s2.0-S2590053624000326-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590053624000326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Since the outbreak of the coronavirus disease 2019 (COVID-19) epidemic in 2019, the public health system has faced enormous challenges. Tracking the individuals who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key step for interrupting chains of transmission of SARS-CoV-2 and reducing COVID-19-associated mortality. With the increasing of asymptomatic infections, it is difficult to track asymptomatic infections through epidemiological surveys and virus whole-genome sequencing. However, due to the cross-reactivity of neutralizing antibodies produced by multiple virus subtypes, neutralizing antibody detection cannot be used to determine whether an individual has a history of infection with a specific subtype of SARS-CoV-2. We recruited 4 human leukocyte antigen A2 (HLA-A2) infections, 15 individuals who received three doses of inactivated vaccines, and 30 breakthrough infections after vaccination and discussed a case-tracking approach to detect epitope-specific CD8+ T cells in the peripheral blood of close contacts, including accurate HLA typing based on ribonucleic acid (RNA)-sequencing and flow cytometry data and the comparison and characterization of SARS-CoV-2 HLA-A2 and HLA-A24 epitope-specific CD8+ T cells. From individuals who received three doses of inactivated vaccine, we observed that the CD8+ T cell specificity for ancestral epitopes was significantly higher than for mutated epitopes, and the fold change of CD8+ T cells corresponding to mutated epitopes relative to ancestral epitopes was less than 1. The enzyme-linked immunospot (ELISpot) results further validate this result. This study forms a “method for understanding the infection history of SARS-CoV-2 subtypes based on the proportion of epitope-specific CD8+ T cells in the peripheral blood of subjects”, covering up to 46 % of the population, including HLA-A2+ and HLA-A24+ donors, providing a novel method for SARS-CoV-2 infected case tracing.

通过表位特异性 CD8+ T 细胞检测鉴定 SARS-CoV-2 感染突变体的新方法
自 2019 年爆发冠状病毒病 2019(COVID-19)疫情以来,公共卫生系统面临着巨大的挑战。追踪严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)检测呈阳性的个体是阻断 SARS-CoV-2 传播链、降低 COVID-19 相关死亡率的关键一步。随着无症状感染的增加,很难通过流行病学调查和病毒全基因组测序来追踪无症状感染。然而,由于多种病毒亚型产生的中和抗体具有交叉反应性,中和抗体检测不能用于确定个人是否有感染特定亚型 SARS-CoV-2 的历史。我们招募了 4 名人类白细胞抗原 A2 (HLA-A2) 感染者、15 名接种了三剂灭活疫苗的患者和 30 名接种疫苗后出现突破性感染的患者,并讨论了一种病例追踪方法,以检测密切接触者外周血中表位特异性 CD8+ T 细胞、包括根据核糖核酸 (RNA) 测序和流式细胞仪数据进行准确的 HLA 分型,以及比较和鉴定 SARS-CoV-2 HLA-A2 和 HLA-A24 表位特异性 CD8+ T 细胞。我们从接种了三剂灭活疫苗的个体中观察到,CD8+ T 细胞对祖先表位的特异性明显高于对变异表位的特异性,变异表位相对于祖先表位的 CD8+ T 细胞的折合变化小于 1。这项研究形成了一种 "基于受试者外周血中表位特异性 CD8+ T 细胞比例了解 SARS-CoV-2 亚型感染史的方法",覆盖人群高达 46%,包括 HLA-A2+ 和 HLA-A24+ 供体,为 SARS-CoV-2 感染病例追踪提供了一种新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biosafety and Health
Biosafety and Health Medicine-Infectious Diseases
CiteScore
7.60
自引率
0.00%
发文量
116
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信